Vanguard Group Inc. Cuts Stake in Celularity Inc. (NASDAQ:CELU)

Vanguard Group Inc. lowered its position in Celularity Inc. (NASDAQ:CELU) by 89.7% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 384,918 shares of the company’s stock after selling 3,348,288 shares during the quarter. Vanguard Group Inc.’s holdings in Celularity were worth $2,013,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Celularity Stock Up 2.7 %

Shares of CELU opened at $3.14 on Tuesday. The stock has a 50 day simple moving average of $3.01 and a two-hundred day simple moving average of $3.73. Celularity Inc. has a 1 year low of $1.59 and a 1 year high of $7.97.

Celularity Profile

Celularity Inc, a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease.